ChemoCentryx Initiates Phase II Clinical Trial for CCX168 a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis

MOUNTAIN VIEW Calif. Oct. 17 2011 PRNewswire ChemoCentryx Inc. today announced the initiation of a Phase II clinical trial for CCX168 an orallyadministered small molecule for the treatment of antineutrophil cytoplasmic antibody ANCAassociated vasculitis A...